Related Experiment Video
Updated: Aug 27, 2026

Direct Restart of a Replication Fork Stalled by a Head-On RNA Polymerase
Published on: April 29, 2010
Reply
Anna S Lok1, William G Powderly2
1Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI.
Insights
Sustained virologic response (SVR) and direct-acting antiviral agents (DAAs) effectively treat chronic hepatitis C, improving patient outcomes. Continued research and ethical considerations support widespread treatment for all patients.
Area of Science:
- Hepatology
- Virology
- Clinical Medicine
Background:
- The efficacy of direct-acting antiviral agents (DAAs) in treating chronic hepatitis C and achieving sustained virologic response (SVR) is supported by extensive clinical and observational data.
- Despite accumulating evidence, the Cochrane Group has not yet recognized SVR as a validated surrogate outcome for hepatitis C treatment.
Discussion:
- The authors express disappointment with the Cochrane Group's continued skepticism regarding SVR and DAA efficacy.
- Numerous studies published since 2017 reinforce the clinical and patient-reported benefits of SVR and DAAs.
- A notable outcome is the observed reduction in patients requiring liver transplantation due to hepatitis C.
Key Insights:
- SVR achieved through DAAs significantly improves clinical and patient-reported outcomes in chronic hepatitis C.
- Evidence from global clinical trials and observational studies robustly supports the benefits of DAA therapies.
- There is a documented decrease in the number of patients listed for liver transplantation for hepatitis C.
Outlook:
- The ethical imperative to treat all patients with chronic hepatitis C is underscored by the proven benefits of current therapies.
- Further research may solidify SVR as a universally accepted surrogate endpoint in hepatitis C clinical trials.
- Continued advocacy for widespread DAA treatment is crucial for improving global hepatitis C management.
Abstract:
We are disappointed that the Cochrane Group remains unconvinced that sustained virologic response (SVR) is a validated surrogate outcome and that direct-acting antiviral agents (DAAs) have been demonstrated to improve clinical as well as patient-reported outcomes in patients with chronic hepatitis C. Since our commentary in 2017, there have been many more studies supporting the benefits of SVR and DAA therapies, including a decline in patients added to the waiting list for liver transplantation for hepatitis C. We recognize that randomized controlled trials are the gold standards for showing the benefits of new treatments but given the robust evidence from clinical trials and observational studies all over the world, we do not believe that it is ethical to contemplate withholding clinically proven beneficial therapy. We stand by our associations' recommendations that all patients with chronic hepatitis C should be treated. This article is protected by copyright. All rights reserved.
Related Concept Videos
Responses to Salt Stress
Reaction Yield
Reaction Rate
The mathematical representation of the change in the concentration of reactants and products, over time, is the rate...
Reaction Mechanisms
For instance, the decomposition of ozone appears to follow a mechanism with two steps:
Reaction Quotient
Support Reactions
The purpose of the supports is to prevent the translational motion of the system by applying an equal and opposite force and to prevent the system's rotation by applying a...

